Wang Kai, Wang YuQin, Li YingHui, Fang Bo, Li Bo, Cheng Wei, Wang Kun, Yang SuMin
Department of Cardiovascular Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao 266021, China.
iScience. 2024 Jul 20;27(8):110524. doi: 10.1016/j.isci.2024.110524. eCollection 2024 Aug 16.
RNA methylation has emerged as a dynamic regulatory mechanism that impacts gene expression and protein synthesis. Among the known RNA methylation modifications, N6-methyladenosine (mA), 5-methylcytosine (mC), 3-methylcytosine (mC), and N7-methylguanosine (mG) have been studied extensively. In particular, mA is the most abundant RNA modification and has attracted significant attention due to its potential effect on multiple biological processes. Recent studies have demonstrated that RNA methylation plays an important role in the development and progression of cardiovascular disease (CVD). To identify key pathogenic genes of CVD and potential therapeutic targets, we reviewed several common RNA methylation and summarized the research progress of RNA methylation in diverse CVDs, intending to inspire effective treatment strategies.
RNA甲基化已成为一种影响基因表达和蛋白质合成的动态调控机制。在已知的RNA甲基化修饰中，N6-甲基腺苷（mA）、5-甲基胞嘧啶（mC）、3-甲基胞嘧啶（mC）和N7-甲基鸟苷（mG）已得到广泛研究。特别是，mA是最丰富的RNA修饰，因其对多种生物学过程的潜在影响而备受关注。最近的研究表明，RNA甲基化在心血管疾病（CVD）的发生和发展中起重要作用。为了确定CVD的关键致病基因和潜在治疗靶点，我们综述了几种常见的RNA甲基化，并总结了RNA甲基化在各种CVD中的研究进展，旨在启发有效的治疗策略。
